A pilot study of combination chemotherapy with S-1 and low-dose cisplatin for highly advanced gastric cancer

Anticancer Research

Volumn 26, Issue 2 B, 2006, Pages 1631-1635

  Takahashi, Tsunehiro ^a   Saikawa, Yoshiro ^a   Yoshida, Masashi ^a   Kitagawa, Yuko ^a   Otani, Yoshihide ^a   Kubota, Tetsuro ^a   Kumai, Koichiro ^a   Kitajima, Masaki ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

Cisplatin; Combination chemotherapy; Gastric cancer; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; ANTINEOPLASTIC AGENT; CISPLATIN; DOCETAXEL; IRINOTECAN; PACLITAXEL; TAXANE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LEUKOPENIA; LIVER DISEASE; LOW DRUG DOSE; MALE; NAUSEA; NEUTROPENIA; PIGMENT DISORDER; PRIORITY JOURNAL; PROGNOSIS; SIDE EFFECT; STOMACH CANCER; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; OXONIC ACID; PILOT PROJECTS; PYRIDINES; STOMACH NEOPLASMS; TEGAFUR;

EID: 33645818388     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Japanese Gastric Cancer Association: Introduction to JGCA Gastric Cancer Treatment Guidelines. Tokyo: Kanehara: pp. 4-6, 2001.
2. Hundahl SA, Phillips JL and Menck HR: The National Cancer Data Base report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: fifth edition American Joint Committee on Cancer staging, proximal disease, and the "different disease" hypothesis. Cancer 88: 921-932, 2000.
3. Landry J, Tepper JE, Wood WC, Moulton EO, Koerner F and Sullinger J: Patterns of failure following curative resection of gastric cancer. Int J Radiat Oncol Biol Phys 191: 1357-1362, 1990.
4. Shirasaka T, Nakano K, Takeuchi T, Satake H, Uchida J, Fujioka A, Saito H, Okabe H, Oyama K, Takeda S, Unemi N and Fukushima M: Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydropyrimidine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted in nude rat. Cancer Res 56: 2602-2606, 1996.
5. Shirasaka T, Shimamoto Y and Fukushima M: Inhibition by oxanic acid of gastrointestinal toxicity of 5-fluorourail without loss of its antitumor activity in rats. Cancer Res 53: 4004-4009, 1993.
6. Fukushima M, Satake H, Uchida J, Shimamoto Y, Kato T, Takechi T, Okabe H, Fujioka A, Nakano K, Ohshimo H, Takeda S and Shirasaka T: Preclinical antitumor efficacy of S-1: a new oral formulation of 5-fluorouracil on human tumor xenografts. Int J Oncol 13: 693-698, 1998.
7. Harris BE, Song R, Soong ST and Diasio RB: Relationship between dihydropyrimidine dehydrogenase activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 50: 197-201, 1990.
8. Shirasaka T, Shimamoto Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K and Fukushima M: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7: 548-557, 1996.
9. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y and Taguchi T: Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 34: 1715-1720, 1998.
10. Koizumi W, Kurihara M, Nakano S and Hasegawa K: Phase II study of S-1, a novel derivative 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology 58: 191-197, 2000.
11. Cantrell JE, Hart RD, Taylor RF and Harvey JH: Pilot trial of continuous-infusion 5-fluorouracil and weekly cisplatin in advanced colorectal cancer. Cancer Treat Rep 71: 615-618, 1987.
12. LoRusso P, Pazdur R, Redman BG, Kinzie J and Vaitkevicius V: Low-dose continuous infusion 5-fluorouracil and cisplatin: phase II evaluation in advanced colorectal carcinoma. Am J Clin Oncol 12: 486-490, 1989.
13. Japanese Research Society for Gastric Cancer: Japanese Classification of Gastric Carcinoma. 16th edition. Kanahara, Tokyo, 2001.
14. Official reference of CTC version 2.0: Cancer therapy evaluation program. Common toxicity criteria. Version 2.0. DCTD, NCI, NIH, DHHS, 1998.
15. Louvet C, Andre T, Tigaud JM, Gamelin E, Douillard JY, Brunet R, Francois E, Jacob JH, Levoir D, Taamma A, Rougier P, Cvitkovic E and de Gramount A: Phase II study of oxaliplatin, fluorouracil, and folic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol 20: 4543-4548, 2002.
16. Koizumi W, Fukuyama Y, Fukuda T, Akiya T, Hasegawa K, Kojima Y, Ohno N and Kurihara M: Randomized phase II study comparing mitomycin, cisplatin plus doxifluridine with cisplatin plus doxifluridine in advanced unresectable gastric cancer. Anticancer Res 24: 2465-2470, 2004.
17. Souglakos J, Syrigos K, Potamianou A, Polyzos A, Boukovinas I, Androulakis N, Kouroussis Ch, Vardakis N, Christophilakis Ch, Kotsakis A and Georgoulias V: Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: a multicentre phase II trial. Ann Oncol 15: 1204-1209, 2004.
18. Chao Y, Yeh KH, Chang CJ, Chen LT, Chao TY, Wu MF, Chang CS, Chang JY, Chung CY, Kao WY, Hsieh RK and Cheng AL: Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer. Br J Cancer 91: 453-458, 2004.
19. Wils J: The treatment of advanced gastric cancer. Semin Oncol 23: 397-406, 1996.
20. Moynihan T, Hansen R and Anderson T: Continuous 5-fluorouracil infusion in advanced gastric carcinoma. Am J Clin Oncol 11: 461-464, 1988.
21. Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA and Fryer JG: A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program Study. J Clin Oncol 7: 425-432, 1989.
22. Wils JA, Klein HO, Wagener DJ, Bleiberg H, Reis H, Korsten F, Conroy T, Fickers M, Leyvraz S, Buyse M et al: Sequential high-dose methotrexate and fluorouracil combined with doxorubicin. A step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Group. J Clin Oncol 9: 827-831, 1991.
23. Kelsen D, Atiq OT, Saltz L, Niedzwiecki D, Ginn D, Chapman D, Heelan R, Lightdale C, Vinciguerra V and Brennan M: FALMTX versus etoposide doxorubicin, and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol 10: 541-548, 1992.
24. Kim NK, Park YS, Heo DS, Suh C, Kim SY, Park KC, Kang YK, Shin DB, Kim HT, Kim HJ et al: A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 71: 3813-3818, 1993.
25. Vanhoefer U, Rougier P, Wilke H, Ducreux MP, Lacave AJ, Van Cutsem E, Planker M, Santos JG, Piedbois P, Paillot B, Bodenstein H, Schmoll HJ, Bleiberg H, Nordlinger B, Couvreur ML, Baron B and Wils JA: Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Group. J Clin Oncol 18: 2648-2657, 2000.
26. Kondo K, Murase M, Kodera Y, Akiyama S, Ito K, Yokoyama Y, Takagi H and Shirasaka T: Feasibility study on protracted infusional 5-fluorouracil and consecutive low-dose cisplatin for advanced gastric cancer. Oncology 53: 64-67, 1996.
27. Chung YS, Yamashita Y, Inoue T, Matsuoka T, Nakata B, Onoda N, Maeda K, Sawada T, Kato Y, Shirasaka T and Sowa M: Continuous infusion of 5-fluorouracil and low dose cisplatin infusion for the treatment of advanced or recurrent gastric adenocarcinoma. Cancer 80: 1-7 1997.
28. Saikawa Y, Akasaka Y, Kanai T, Otani Y, Kumai K, Kubota T and Kitajima M: Preoperative combination chemotherapy with S-1 and low dose cisplatin against highly advanced gastric cancer. Oncol Rep 10: 381-386, 2003.